TF
Highly rated in
12
conditions
Highly rated in
12
conditions
Check Dr. Thomas W. Flaig's experience treating your condition:
About Dr. Thomas W. Flaig

Thomas Flaig is an Oncologist and a Hematologist Oncology expert in Aurora, Colorado. Flaig has been practicing medicine for over 24 years and is highly rated in 12 conditions, according to our data. His top areas of expertise are Bladder Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Hormone Replacement Therapy (HRT). He is licensed to treat patients in Colorado. Flaig is currently accepting new patients.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 13 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Thomas W. Flaig it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Thomas W. Flaig accepts the following insurance:

  •  Ambetter
  •  Bright Health
  •  Medica

Call to see if your plan is accepted.
Locations
1665 Aurora Ct, Aurora, CO 80045
Other Locations
12605 E 16th Ave, Aurora, CO 80045
Background & Education
Graduate Institution
University Of Minnesota Medical School, 1999
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
UCHealth Broomfield Hospital
UCHealth University Of Colorado Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized, Pragmatic, Adaptive Trial of Metformin for Glucose Intolerance or Increased Body Mass Index in Prostate Cancer Patients
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
View 12 Less Clinical Trials -

119 Total Publications

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors